The Humira Biosimilar Delay Antitrust Class Action refers to legal challenges against AbbVie alleging the company used anticompetitive tactics to delay cheaper biosimilar versions of Humira, one of the world’s most expensive medications. In March 2019, the UFCW Local 1500 Welfare Fund filed a class-action lawsuit in federal court claiming AbbVie illegally maintained a “patent thicket” of over 130 patents to block competitors from entering the market, even after Humira’s primary patent expired in 2016. The case represents one of the pharmaceutical industry’s most significant antitrust disputes, with implications for how drug manufacturers can protect their market share against biosimilar competition.
Although the initial lawsuit was dismissed and appeals upheld that dismissal, the Humira antitrust dispute highlights a critical gap between patent law protections and competitive market dynamics. Humira became the first drug to reach $20 billion in annual sales, making it a financial powerhouse for AbbVie. The delay tactics allegedly kept biosimilars out of the U.S. market until 2023—five years after European approval in 2018—prolonging the period when patients and insurers faced premium prices for the drug.
Table of Contents
- How Did AbbVie Allegedly Delay Humira Biosimilars?
- What Happened in Court?
- The Patent Thicket Strategy and Its Implications
- What Was the Role of Settlement Agreements?
- Why Was the Case Dismissed?
- Impact on Biosimilar Access and Pricing
- What Happened After the Case Dismissed?
- Conclusion
How Did AbbVie Allegedly Delay Humira Biosimilars?
AbbVie’s alleged anticompetitive strategy centered on securing 132 patents designed specifically to create barriers against biosimilar entry. Rather than relying solely on the primary patent, which expired in 2016, the company filed numerous secondary patents covering minor formulation changes, delivery mechanisms, manufacturing processes, and combination therapies. This fragmented patent landscape forced biosimilar manufacturers to navigate complex patent challenges or negotiate settlement agreements that favored AbbVie’s timeline. The company also pursued settlement agreements with major biosimilar competitors, including Amgen and Samsung Bioepis.
These settlements allowed the companies to enter the European market in 2018 but delayed U.S. market entry until 2023. This geographic split reflected a common antitrust concern: that competitors agreed to stagger their market entry rather than compete on price and innovation. Senators Chuck Grassley and Amy Klobuchar explicitly urged the Federal Trade Commission to investigate these “pay-for-delay” settlement strategies, comparing them to litigation tactics that had been challenged in other pharmaceutical cases.
What Happened in Court?
The case faced an immediate legal obstacle. In June 2020, Judge Manish Shah of the Northern District of Illinois granted AbbVie’s motion to dismiss, ruling that the plaintiffs’ antitrust allegations were too speculative. The court found that the complaint didn’t adequately prove AbbVie had engaged in illegal monopolization or that its patent filings constituted predatory conduct rather than legitimate patent protection.
Judge Shah’s decision reflected a broader judicial skepticism about antitrust claims in pharmaceutical cases, where patent portfolios are common and difficult to distinguish from anticompetitive behavior. The Seventh Circuit Court of Appeals affirmed the dismissal in August 2022, with Judge Easterbrook emphasizing that plaintiffs failed to state a plausible antitrust violation under existing precedent. This outcome disappointed consumer advocates and generic drug advocates, as it signaled courts were unwilling to second-guess pharmaceutical companies’ patenting strategies. The dismissal was particularly significant because it ended the class action without any settlement or judgment against AbbVie, meaning no compensation was awarded to patients or insurers who paid inflated Humira prices during the alleged delay period.
The Patent Thicket Strategy and Its Implications
The concept of a “patent thicket” involves filing numerous overlapping patents to create a complex landscape that competitors must navigate. In Humira’s case, AbbVie filed patents covering the drug’s molecular structure, its combination with other therapies, specific dosing regimens, pen injector designs, and manufacturing methods. This approach isn’t illegal by itself—companies routinely protect innovations through multiple patents. However, critics argue the strategy becomes anticompetitive when patents lack genuine innovation and exist primarily to block competitors.
The practical impact on consumers was substantial. Humira’s annual cost for patients often exceeded $60,000 without insurance coverage, and even with insurance, patients faced high copayments. The delay in biosimilar availability meant millions of patients continued paying these premium prices years longer than might have occurred in a competitive market. When Simlandi finally launched as the first high-concentration interchangeable adalimumab biosimilar in 2024, it offered a 40mg/0.4ml concentration that represented a significant step toward price competition, but this came nearly a decade after Humira’s primary patent expired.
What Was the Role of Settlement Agreements?
Settlement agreements between AbbVie and biosimilar manufacturers became a central point of investigation. Rather than fighting patent disputes in court, competitors negotiated agreements that allowed them market entry—but on AbbVie’s terms regarding timing and territory. The arrangement allowing European market entry in 2018 while delaying U.S. entry to 2023 exemplified this dynamic. From AbbVie’s perspective, these settlements were efficient business decisions.
From a consumer protection standpoint, they represented potential collusion that artificially extended AbbVie’s market exclusivity. Congressional scrutiny focused specifically on whether these settlements constituted “pay-for-delay” arrangements—a term applied when brand-name manufacturers pay generics or biosimilars to delay their market entry. The Federal Trade Commission has historically challenged such agreements, successfully blocking several in previous cases. However, in the Humira context, courts found the plaintiffs hadn’t adequately proven AbbVie’s behavior crossed the legal line into illegal monopolization. This outcome reflected the difficulty of winning antitrust cases in the pharmaceutical sector, where patent protection is legitimate and settlement agreements are common business practice.
Why Was the Case Dismissed?
Courts applying antitrust law to pharmaceutical patent disputes face a fundamental tension: patents grant legal monopolies by design, yet antitrust law prohibits monopolistic conduct. The Seventh Circuit resolved this tension by deferring to patent holders’ legitimate rights. The court found that AbbVie’s patent filings and settlements, while possibly aggressive, fell within the scope of patent law protections.
To establish illegal conduct, plaintiffs would need to prove AbbVie knew its patents were invalid or obtained them through fraud—a much higher bar than simply showing competitive harm. A critical limitation of the court’s approach is that it may overlook situations where legitimate patent tools are weaponized to block competition beyond what patent law intends. The dismissal also meant no judicial examination of whether the 132 patents served genuine innovation or primarily created litigation burden for competitors. From a plaintiff’s perspective, this outcome exposed a gap in antitrust enforcement: current law may not adequately address strategies that combine legitimate patents with settlement agreements to extend market exclusivity beyond what the original patent term would have provided.
Impact on Biosimilar Access and Pricing
The Humira case illuminated how intellectual property disputes directly affect patient access to more affordable medications. Adalimumab biosimilars eventually launched, but years of delay meant patients and insurers continued paying premium prices. When biosimilar competition finally arrived in 2024, prices began declining significantly, with Simlandi’s high-concentration formulation capturing over 85% of new prescriptions within months of launch.
This rapid adoption demonstrated substantial pent-up demand for more affordable options. The case also influenced the pharmaceutical industry’s approach to biosimilar commercialization. Manufacturers became more cautious about potential antitrust challenges, and regulatory agencies increased scrutiny of settlement agreements. However, the dismissal provided limited deterrence against future patent strategies, as courts essentially validated AbbVie’s approach by ruling the conduct lawful.
What Happened After the Case Dismissed?
Following the August 2022 dismissal, the biosimilar landscape for adalimumab continued evolving despite the antitrust case’s legal failure. The patent thicket AbbVie created remained in place, but biosimilar manufacturers found ways to navigate around it or license specific rights through continued negotiations. By 2024, multiple adalimumab biosimilars competed in the U.S.
market, including offerings from Amgen, Sandoz, Samsung Bioepis, and others, finally creating meaningful price competition. Looking forward, the Humira case may influence future antitrust scrutiny of pharmaceutical patent strategies, particularly as the Federal Trade Commission and Department of Justice have signaled increased interest in challenging “reverse settlement” agreements and patents filed primarily to delay competition. While this specific case didn’t result in antitrust liability, it raised awareness among policymakers and advocates about gaps in current law, potentially paving the way for future enforcement actions against similar conduct by other manufacturers.
Conclusion
The Humira Biosimilar Delay Antitrust Class Action ultimately failed to hold AbbVie liable for anticompetitive conduct, but it highlighted a genuine vulnerability in antitrust enforcement for pharmaceutical patents. The case demonstrated how legitimate patent tools can be deployed strategically to extend market exclusivity and delay biosimilar competition, even after a drug’s primary patent expires. Patients and insurers paid the price—literally—through years of premium pricing while the legal system sorted through complex questions about what constitutes unlawful monopolization versus permitted patent protection.
For anyone concerned about pharmaceutical pricing and biosimilar access, the Humira case serves as a reminder that legal victories aren’t always necessary to achieve market change. Biosimilars eventually entered the market, prices declined, and patient access improved—outcomes that would have happened faster without the alleged delay tactics, but that occurred regardless of the lawsuit’s dismissal. Moving forward, patient advocates, policymakers, and the pharmaceutical industry continue debating how to balance legitimate innovation incentives with the need for competitive generic and biosimilar markets that keep medications affordable.